1. Home
  2. FVRR vs DMAC Comparison

FVRR vs DMAC Comparison

Compare FVRR & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Fiverr International Ltd. no par value

FVRR

Fiverr International Ltd. no par value

HOLD

Current Price

$11.00

Market Cap

372.4M

ML Signal

HOLD

Logo DiaMedica Therapeutics Inc.

DMAC

DiaMedica Therapeutics Inc.

HOLD

Current Price

$7.06

Market Cap

393.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FVRR
DMAC
Founded
2010
2000
Country
Israel
United States
Employees
N/A
N/A
Industry
Business Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
372.4M
393.3M
IPO Year
2019
2018

Fundamental Metrics

Financial Performance
Metric
FVRR
DMAC
Price
$11.00
$7.06
Analyst Decision
Buy
Strong Buy
Analyst Count
9
4
Target Price
$18.43
$15.50
AVG Volume (30 Days)
706.2K
250.8K
Earning Date
04-29-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$500,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$1.83
N/A
P/E Ratio
$22.05
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.58
$4.01
52 Week High
$28.00
$10.42

Technical Indicators

Market Signals
Indicator
FVRR
DMAC
Relative Strength Index (RSI) 52.41 51.05
Support Level $9.93 $5.51
Resistance Level $11.43 $7.06
Average True Range (ATR) 0.45 0.52
MACD 0.04 -0.10
Stochastic Oscillator 45.16 22.45

Price Performance

Historical Comparison
FVRR
DMAC

About FVRR Fiverr International Ltd. no par value

Fiverr International Ltd operates a online marketplace that enables sellers to offer digital services and buyers to purchase them The Company's platform features an extensive catalog of digital services that spans over hundreds of categories. Buyers can purchase digital services ranging from simple services such as logo design and blog post writing, to complex services such as video creation, website development and social media marketing. Also, the Company offers value-added services including subscription products, advertising solutions and financial tools designed to support marketplace users and enhance their business activities. The company generates maximum of its revenue from USA.

About DMAC DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.

Share on Social Networks: